AbbVie reported quarterly EPS of $2.65, beating the Zacks Consensus Estimate of $2.62 by $0.03 per share and improving from $2.46 a year ago. The result is a modest earnings beat of about 1.1% versus consensus, indicating stable fundamentals. The headline should be mildly supportive for ABBV shares, but the article provides no additional guidance or revenue details.
AbbVie reported quarterly EPS of $2.65, beating the Zacks Consensus Estimate of $2.62 by $0.03 per share and improving from $2.46 a year ago. The result is a modest earnings beat of about 1.1% versus consensus, indicating stable fundamentals. The headline should be mildly supportive for ABBV shares, but the article provides no additional guidance or revenue details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
